William Blair Downgrades Sequenom (SQNM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Buy Sequenom (SQNM) Aggressively, Issues 'Not End of World' - Wedbush
July 25, 2013 9:43 AM EDTWedbush today maintained an Outperform rating on Sequenom (NASDAQ: SQNM) with a price target of $5.00. Shares tumbled as a result of disappointing earnings on Wednesday. Along with many other companies in the diagnostics industry, Sequenom experienced delays in receipt of payments as a result of... More
Ladenburg Thalmann Downgrades Sequenom (SQNM) to Neutral
July 25, 2013 8:24 AM EDTLadenburg Thalmann downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
Lazard Capital Downgrades Sequenom (SQNM) to Neutral
July 25, 2013 7:16 AM EDTLazard Capital downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
Sequenom, Inc. (SQNM) Posts Q2 Loss of 27c/Share; Issues MaterniT21 PLUS Update
July 24, 2013 4:08 PM EDTSequenom, Inc. (NASDAQ: SQNM) reported Q2 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $46.25 million.
Operations Update
The annualized run rate for the MaterniT21 PLUS test at the end of the second quarter surpassed 150,000 samples.
"We have managed through challenges associated with the tremendous growth in our business following the launch of MaterniT21 PLUS. Uncertainties associated with the newly introduced coding changes in the molecular... More
